Few small-cap health-tech stories have shifted direction as sharply as Mangoceuticals, Inc. (NASDAQ: MGRX), the telemedicine company now attempting to reinvent itself through a proposed pivot into nuclear technology. As September 2026 unfolds, the Nasdaq-listed men's-health platform is juggling a looming listing-compliance deadline, a …
Manhattan Scientifics, Inc (OTC:MHTX) is the kind of long-lived, technology-focused micro-cap that periodically resurfaces in speculative trading chatter, and the ticker has drawn renewed attention after a sharp move. The framing warrants an important caveat up front: in an over-the-counter name quoted at a …
Meihua International Medical Technologies (OTC:MHUAF) is a name that now sits well off the radar of most U.S. investors, and for good reason. The China-based medical-device manufacturer was pushed off the Nasdaq in late 2025 and now changes hands in the over-the-counter market, where …
● Milestone Pharmaceuticals is a biopharmaceutical company focused on cardiovascular conditions, led by etripamil, a calcium channel blocker delivered as a nasal spray for paroxysmal supraventricular tachycardia, or PSVT, a rapid heart-rhythm disorder.
Before reading anything into a double-digit percentage swing, it is worth knowing what actually sits behind the ticker. Lotus Pharmaceuticals, Inc (OTC: LTUS) is not a conventional, exchange-listed operating company but a sub-penny stock trading on the OTC market and described by data providers …
MabCure, Inc (OTC:MBCI) is the kind of obscure micro-cap that rarely surfaces outside of ticker screens, yet its focus, antibody-based early cancer detection, touches one of medicine's most sought-after goals. The reality behind MBCI is far more modest: a tiny development-stage company that has …
Mustang Bio, Inc. (NASDAQ: MBIO), a cell-and-gene-therapy developer, sits in a precarious spot on Nasdaq: its shares trade well below $1 and the company is racing a listing-compliance clock. The stock eased modestly in recent trading, but the more consequential backdrop is a Nasdaq …
● Few small-cap biotech names capture the tension between clinical promise and financial fragility as vividly as Moleculin Biotech.
A quote of a hundred-thousandth of a cent tends to tell its own story. Medican Enterprises Inc (OTC:MDCN) trades on the over-the-counter market at effectively nothing, and the flat tape reflects a company that stopped reporting to regulators years ago rather than one poised …
Medicus Pharma Ltd (NASDAQ: MDCX) enters the autumn as a company mid-reinvention. The clinical-stage drug developer, which trades below 20 cents and carries a market value of only about $11 million, has begun repositioning itself as a precision oncology-led biotechnology business. With a fresh …